Medpace Holdings, Inc. (MEDP) Position Lifted by Granite Investment Partners LLC
Granite Investment Partners LLC increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 295,415 shares of the company’s stock after purchasing an additional 15,486 shares during the period. Granite Investment Partners LLC owned approximately 0.79% of Medpace Holdings worth $9,424,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Tudor Investment Corp ET AL increased its position in shares of Medpace Holdings by 16.4% in the first quarter. Tudor Investment Corp ET AL now owns 6,864 shares of the company’s stock worth $205,000 after purchasing an additional 967 shares during the period. Federated Investors Inc. PA increased its position in shares of Medpace Holdings by 3.1% in the second quarter. Federated Investors Inc. PA now owns 184,469 shares of the company’s stock worth $5,350,000 after purchasing an additional 5,554 shares during the period. Vanguard Group Inc. increased its position in shares of Medpace Holdings by 12.4% in the first quarter. Vanguard Group Inc. now owns 822,842 shares of the company’s stock worth $24,562,000 after purchasing an additional 90,742 shares during the period. Osborn Williams & Donohoe LLC bought a new position in shares of Medpace Holdings in the second quarter worth $326,000. Finally, Prudential Financial Inc. increased its position in shares of Medpace Holdings by 138.2% in the second quarter. Prudential Financial Inc. now owns 81,870 shares of the company’s stock worth $2,374,000 after purchasing an additional 47,500 shares during the period. Institutional investors own 17.94% of the company’s stock.
Medpace Holdings, Inc. (NASDAQ MEDP) traded up $0.40 during trading on Tuesday, reaching $36.04. The company’s stock had a trading volume of 106,100 shares, compared to its average volume of 172,481. Medpace Holdings, Inc. has a 1 year low of $21.76 and a 1 year high of $39.64. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68. The company has a market capitalization of $1,340.29, a PE ratio of 24.25, a PEG ratio of 1.83 and a beta of -0.34.
A number of research analysts have issued reports on the company. Raymond James Financial, Inc. assumed coverage on Medpace Holdings in a research report on Friday, September 29th. They issued a “market perform” rating on the stock. KeyCorp reiterated a “hold” rating on shares of Medpace Holdings in a research report on Tuesday, October 17th. Zacks Investment Research cut Medpace Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. William Blair cut Medpace Holdings from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 1st. They noted that the move was a valuation call. Finally, Robert W. Baird reiterated a “hold” rating and issued a $32.00 target price on shares of Medpace Holdings in a research report on Monday, October 9th. Eight analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $36.60.
COPYRIGHT VIOLATION NOTICE: “Medpace Holdings, Inc. (MEDP) Position Lifted by Granite Investment Partners LLC” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/21/medpace-holdings-inc-medp-position-lifted-by-granite-investment-partners-llc.html.
Medpace Holdings Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP).
Receive News & Stock Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related stocks with our FREE daily email newsletter.